Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
Paul C Cremer, Antonio Abbate, Kristin M. Hudock, Carla Sue McWilliams et autres
us (code pays fourni par la source)
69 citations
The Lancet Rheumatology